NCT01043510View on ClinicalTrials.gov

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin degludec

0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days

DRUG

insulin detemir

0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days

Trial Locations (1)

91911

Novo Nordisk Investigational Site, Chula Vista

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY